Investor Relations
Company Overview
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,300 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
Recent Press Releases
Upcoming Events & Webcasts
Recent Events & Webcasts
Date | Event Details | Remind Me |
---|---|---|
Summary Toggle
Jan 9, 2019 3:30 PM EST
|
||
Summary Toggle
Nov 29, 2018 9:30 AM EST
|
||
Summary Toggle
Nov 15, 2018 10:30 AM EST
|
||
Summary Toggle
Nov 8, 2018 4:30 PM EST
|
||
Summary Toggle
Sep 12, 2018 4:50 PM EDT
|
||
Summary Toggle
Sep 5, 2018 9:05 AM EDT
|
||
Summary Toggle
Aug 7, 2018 4:30 PM EDT
|
||
Summary Toggle
May 22, 2018 3:00 PM EDT
|
||
Summary Toggle
May 15, 2018 10:55 AM PDT
|
LocationThe Encore in Las Vegas, NV
|
|
Summary Toggle
May 8, 2018 4:30 PM EDT
|
||
Summary Toggle Apr 16, 2018 from 10:00 AM to 11:00 AM CDT |
Speakers will include: Below are a subset of abstracts that best illustrate the unique capabilities of NanoString’s technology platform. A complete list of 51 NanoString-enabled abstracts follows. Digital Spatial Profiling Title: Digital spatial profiling platform allows for spatially-resolved, high-plex quantification of mRNA distribution and abundance on FFPE and fresh frozen tissue sections Title: High-plex immune marker spatial profiling quantitation by NanoString® Digital Spatial Profiling technology and quantitative immunofluorescence Title: Validation of Digital Spatial Profiling of Key Immuno-Oncology Targets for Mouse FFPE Preclinical Models PlexSet Abstracts Title: Cross-Comparison of Targeted Gene Expression Technologies for Patient Stratification Gene Expression Profiling Title: Infiltrating immune cells in breast cancer subtypes Title: The immune microenvironment in hormone receptor-positive breast cancer and treatment outcome following preoperative chemotherapy plus bevacizumab Title: Prognostic gene signature use in checkpoint inhibitor monotherapy for melanoma Title: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms Title: Comprehensive immune and molecular analysis of two metastatic melanoma patients treated with a personal neoantigen vaccine, NEO-PV-01, in combination with anti-PD1: A case study Location Hall A of McCormick Place South
|
|
Summary Toggle Apr 14 - Apr 18, 2018 |
LocationChicago, Illinois
|
|
Summary Toggle
Mar 13, 2018 11:20 AM EDT
|
||
Summary Toggle
Mar 7, 2018 4:30 PM EST
|